In recent years, with the continuous deepening of the reform of China's pharmaceutical market and the continuous improvement of the innovation and R&D environment, multinational pharmaceutical companies are accelerating the pace of development, starting to further cultivate the Chinese market, and accelerate innovation and industrial upgrading
.
Recently, Novo Nordisk announced at the 5th CIIE that it will invest 400 million yuan to establish Novo Nordisk (Shanghai) Investment Co.
, Ltd.
to control its business engines in Chinese mainland production, trade, research and development, etc.
, in order to integrate and optimize business resources in China and coordinate to promote the upgrading
of the layout of the entire industrial chain.
On the same day, it also signed an agreement with the Administrative Committee of Lingang New Area in the cloud, which provides financial support and preferential treatment
for enterprises to support the overall development of Novo Nordisk in the area.
It is understood that from 2019 to 2021, Novo Nordisk completed an investment of more than 500 million yuan in the Tianjin plant and introduced 3 pre-filled injection pen production lines
.
In 2020, it invested RMB 200 million in Lingang New Area of Shanghai Pilot Free Trade Zone to establish Novo Nordisk (Shanghai) Pharmaceutical Trading Co.
, Ltd.
In 2021, Novo Nordisk increased its capital by USD 150 million in China to continue to increase production capacity and build a digital factory
.
In 2022, the foundation stone was laid for the high-bay warehouse at Novo Nordisk's Tianjin production plant, with an investment of about 500 million yuan
.
On November 5, Sumitomo Pharmaceutical announced the official opening and operation
of Sumitomo Pharmaceutical Investment (China) Co.
, Ltd.
as its regional headquarters in China.
In the future, the China Regional Headquarters will serve as the management center of the China region, coordinating and coordinating the entire industry of
drug R&D, production and commercialization in China.
In the next 5-10 years, it hopes to bring more new products that are valuable to Chinese patients to the market in China, such as Lefamulin, a new drug for community-acquired pneumonia, Vibegron, a treatment for overactive bladder, and Ulotaront, a
treatment drug for schizophrenia.
At the same time, Sumitomo Pharmaceutical will try to challenge some new fields, and will also consider and plan to deploy the most cutting-edge fields of new drug development such as oncology and regenerative medicine in China, and will strive to achieve simultaneous development, application and approval
of more new drugs in China.
On October 18, ZEISS' first self-construction project in China was also launched
in Suzhou.
It is reported that ZEISS laid the foundation stone in Suzhou Industrial Park to start the construction of the "Fengqi" project, which is the first self-built project of ZEISS in China to purchase land, marking the further deepening and expansion
of ZEISS' localization process in China.
The completion of the new project will help ZEISS leverage Suzhou's deep manufacturing, talent and industrial chain advantages, accelerate joint innovation with partners, and build a more resilient and sustainable industrial ecosystem in the Yangtze River Delta region
.
In addition, as early as 2004, Roche established an R&D center
in China.
In 2019, Roche invested an additional RMB 863 million to upgrade the R&D center to the new Roche Shanghai Innovation Center
.
In 2021, the Roche China Accelerator, with an investment of nearly RMB 300 million, was launched, empowering the construction of
China's local medical innovation ecosystem.
In 2022, the Roche Shanghai Innovation Center (RICS) was also officially upgraded to the Roche China Innovation Center (CICoR), which has independent decision-making power
for new drug research and early development.
.
.
.
.
.
.
Judging from the fact that many multinational pharmaceutical companies are accelerating their deployment in the Chinese market, China has obviously become one of the important pillars of
the global business of many multinational pharmaceutical companies.
At present, in addition to expanding investment, multinational pharmaceutical companies are also accelerating the introduction of new drugs into China
.
The industry expects that in the future, under the background of the continuous transformation and upgrading of China's pharmaceutical market and the development of high quality, multinational pharmaceutical companies will also invest more, be more targeted and more accurately explore the Chinese market
.
={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"Share to:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
appendChild(createElement('script')).
src='http://bdimg.
share.
baidu.
com/static/api/js/share.
js?v=89860593.
js?cdnversion='+~(-new Date()/36e5)]; 
